[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100629058":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":24,"centralContacts":33,"locations":39,"responsibleParty":55,"collaborators":10,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":59,"sex":65,"minAge":66,"maxAge":10,"enrollmentInfo":67,"targetDuration":10,"studyType":70,"phases":10,"briefSummary":71,"conditions":72,"keywords":10,"overallStatus":41,"whyStopped":10,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Fondazione del Piemonte per l'Oncologia","OTHER",[8,12,15,18,21],{"label":9,"type":10,"description":11,"interventionNames":10},"Cohort 1",null,"600 patients known for breast cancer (N=200), ovarian cancer (N=200) and colorectal cancer (N=200) candidates for germline genetic testing in the context of an oncogenic consultation will be evaluated.",{"label":13,"type":10,"description":14,"interventionNames":10},"Cohort 2A","Subjects with hereditary inheritance (probands): the identification of about 10% (N=60) of probands out of 600 subjects examined (20 for pathology) is assumed",{"label":16,"type":10,"description":17,"interventionNames":10},"Cohort 2B","Subjects identified by genetic counseling as being at risk of being carriers of a hereditary neoplastic syndrome, not proven by genetic tests: a population of 60 subjects, 20 for each type of tumour, with similar clinical characteristics of age and phenotype compared to cohort 2A.",{"label":19,"type":10,"description":20,"interventionNames":10},"Cohort 2C","50 subjects for each type of tumor (colorectal, breast and ovarian cancer), negative results in diagnostic genetic analysis. In selected patients in this cohort, DNA\u002FRNA will be analyzed for the identification of causative genetic variants in genes that have escaped routine diagnostic investigation.",{"label":22,"type":10,"description":23,"interventionNames":10},"Cohort 3","250 patients undergoing radical surgical treatment and with the following characteristics:\n\n* locally advanced breast cancer with triple negative phenotype or with lobular histology (N=50);\n* high-grade serous ovarian carcinoma (N=50);\n* stage III melanoma (N=50);\n* stage IIB and IIIA non-small cell lung cancer (N=50);\n* colon cancer with lymph node involvement and vascular invasion (N=50).",[25,29,31],{"name":26,"affiliation":27,"role":28},"Chiara Lazzari, MD","Fondazione del Piemonte per l'Oncologia-IRCCS Candiolo","STUDY_CHAIR",{"name":30,"affiliation":27,"role":28},"Federico Bussolino, MD",{"name":32,"affiliation":27,"role":28},"Luigia Pace, PhD",[34],{"name":35,"role":36,"phone":37,"phoneExt":10,"email":38},"Vanesa Gregorc, MD","CONTACT","+390119933915","vanesa.gregorc@ircc.it",[40],{"facility":27,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"RECRUITING","Candiolo","Turin","10060","Italy","IT",{"type":48,"coordinates":49},"Point",[50,51],7.59812,44.95858,{"lat":51,"lon":50},[54],{"name":35,"role":36,"phone":37,"phoneExt":10,"email":38},{"type":56,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100629058","a-study-of-biological-genetic-and-constitutional-factors-and-non-invasive-monitoring-to-assess-personal-cancer-risks-100629058",false,"NCT07469709","A Study of Biological, Genetic, and Constitutional Factors and Non-invasive Monitoring to Assess Personal Cancer Risks","A Platform for Assessing Personal Risk of Developing or Recurring of Cancer: Study of Biological, Genetic, and Constitutional Factors and Non-invasive Monitoring of Subclinical Recurrences With Therapeutic Impact","PRO-ACTIVE","Inclusion Criteria:\n\n* Age \\>18 years;\n* Patients with breast cancer, including patients who meet the AIOM criteria for eligibility for BRCA testing and patients with lobular breast cancer;\n* Patients with radically resected colon cancer, including patients with stage III colon cancer and vascular invasion;\n* Patients with ovarian carcinomas;\n* Patients with metastatic melanoma;\n* Patients with stage IIB and IIIA non-small cell lung cancer.\n\nExclusion Criteria:\n\n* Age \\\u003C18 years;\n* Unwillingness or inability to give informed consent","ALL","18 Years",{"count":68,"type":69},850,"ESTIMATED","OBSERVATIONAL","The PRO-ACTIVE study aims to develop a clinical-translational program in the field of cancer prevention in all its phases (primary, secondary, and tertiary) to intervene before the clinical and radiological manifestation of the disease. It starts with risk prediction and leads to early diagnosis of the disease or recurrence in the subclinical phase.\n\nThe PRO-ACTIVE study includes the following activities:\n\n* WP1: Integrated DNA-RNA approach for the identification of hereditary markers of predisposition to tumors\n* WP2: Global biological and molecular analysis of the host and tumor for the prevention and monitoring of recurrences\n* WP3: Analysis of the immunological status for the diagnosis of primary prevention and relapses in correlation to genetic and environmental factors\n* WP4: Study of the tumor microenvironment for recurrence prediction",[73,74,75,76,77],"Breast Cancer","Colo-rectal Cancer","Ovarian Cancer","Melanoma (Skin Cancer)","Non-Small Cell Lung Cancer (MeSH Term: Carcinoma, Non-Small-Cell Lung)","2026-03-09",{"date":80,"type":81},"2026-03-13","ACTUAL",{"date":83,"type":81},"2024-02-01",{"date":85,"type":69},"2027-12-31",{"name":5,"class":6},1]